Joint Special Issue

Host-Pathogen Interactions and Monoclonal Antibody Therapeutics

Message from the Guest Editors

Since the description of the first reliable methodology for developing monoclonal antibodies (mAbs) by Köhler and Milstein in 1975 using the hybridoma technique, tremendous advances in their generation, characterization, engineering and expression have been made. The hybridoma methodology is still used today by several investigators, but new technologies have been developed and described. These new technologies have further increased the importance of mAbs even today, especially during the SARS-CoV-2 pandemic, where a plethora of SARS-CoV-2-specific mAbs have been reported in the literature as potential therapeutic tools. Suggested topics for this Special Issue include, but are not limited to, new mAbs against infectious pathogens, the host immune response, the identification of potential viral antigens and epitopes, and new techniques for mAb discovery, development, production and engineering. There is no limitation on the type of contribution; original articles, brief communications, case reports, and reviews are all welcome. Your valuable input will enrich the current state of knowledge and contribute to the control of infectious diseases.

Guest Editors

Dr. Giuseppe A. Sautto

Cleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL 34987, USA

Dr. Roberta Antonia Diotti

Microbiology and Virology Laboratory, Vita-Salute University, San Raffaele, 20132 Milan, Italy

Deadline for manuscript submissions

closed (15 August 2024)

Participating open access journals:

Pathogens

Impact Factor 3.3
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/135131

Vaccines

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/40957

MDPI